The paradox of triple negative breast cancer: Novel approaches to treatment

Breast Journal

Volumn 18, Issue 1, 2012, Pages 41-51

  Fornier, Monica ^a   Fumoleau, Pierre ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c NONE   (France)

Author keywords

ixabepilone; novel agents; platinum agents; poly(ADP ribose) polymerase; triple negative breast cancer

Indexed keywords

AN 162; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BOSUTINIB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYTOTOXIC AGENT; DASATINIB; DOCETAXEL; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; INIPARIB; IRINOTECAN; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLATINUM; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGISTRY; CANCER RELAPSE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; CYTOTOXICITY; DISTANT METASTASIS; DNA REPAIR; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84855712591     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01175.x     Document Type: Article

References (85)

1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-8. (Pubitemid 46668532)
2. Mersin H, Yildirim E, Berberoglu U, Gulben K,. The prognostic importance of triple negative breast carcinoma. Breast 2008; 17: 341-6.
3. Nishimura R, Arima N,. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008; 15: 303-8.
4. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20: 621-7.
5. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34. (Pubitemid 47219710)
6. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-81.
7. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP,. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113: 2638-45.
8. Kaplan HG, Malmgren JA,. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008; 14: 456-63.
9. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110: 876-84. (Pubitemid 47257667)
10. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502. (Pubitemid 43854964)
11. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008; 113: 608-15.
12. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
13. Iwase H, Yamamoto Y, Kurebayashi J, et al. Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases. J Clin Oncol 2009; 27. Abstract e22122.
14. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G,. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217-26. (Pubitemid 44286991)
15. Liu ZB, Liu GY, Yang WT, et al. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncol Rep 2008; 20: 987-94.
16. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q,. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008; 31: 610-4.
17. Tsang J, Lai TL, Lau DH, Au GK, Chua DT,. Triple-negative breast cancer in Hong Kong Chinese patients. J Clin Oncol 2009; 27. Abstract e22127.
18. Khan A, Tovar YE, Rodriguez C, et al. Incidence of triple negative breast cancer phenotype in a predominantly Hispanic cohort. J Clin Oncol 2009; 27. Abstract e22188.
19. Dawood S, Broglio K, Kau SW, et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 2009; 27: 220-6.
20. Ries LAG,. SEER Cancer Statistics Review, 1974-2004. Bethesda, MD: National Cancer Institute, 2009.
21. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL,. Early onset of breast cancer in a group of British black women. Br J Cancer 2008; 98: 277-81. (Pubitemid 351161260)
22. Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157-66.
23. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123-39. (Pubitemid 351538762)
24. Maiti B, Kundranda MN, Jin T, Spiro TP, Daw HA,. The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol 2009; 27. Abstract 1038.
25. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74. (Pubitemid 32878711)
26. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-23. (Pubitemid 36842560)
27. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andre F,. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 2007; 18: 1285-6. (Pubitemid 47244379)
28. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-10.
29. Irvin WJ Jr, Carey LA,. What is triple-negative breast cancer? Eur J Cancer 2008; 44: 2799-805.
30. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123: 236-40. (Pubitemid 351705215)
31. Nofech-Mozes S, Trudeau M, Kahn HK, et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009; 118: 131-7.
32. Park YH, Chang MH, Lee S, et al. Heterogeneity of triple negative breast cancer (TNBC): TNBC might be divided into two or more subgroups by clinicopathologic findings. Cancer Res 2009; 69 (Suppl 24). Abstract 6032.
33. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Metastatic Breast Cancer. 2008; 2: BINV19, BINV-N. Available at: (accessed September 16, 2009).
34. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 1658-67.
35. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34. (Pubitemid 46698581)
36. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85. (Pubitemid 41170290)
37. Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009; 27: 4693-700.
38. Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008; 19: 1847-52.
39. Tomasevic Z, Radosevic-Jelic L, Tomasevic ZM, Jelic S, Milovanovic Z,. Late relapse in triple negative breast cancer. J Clin Oncol 2009; 27. Abstract e12022.
40. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006; 8: R66.
41. Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9: 29-33.
42. Mehta RS,. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox. J Clin Oncol 2008; 26: 3286-8. Author reply 3288.
43. Koya S, Li Y, McDaniel SA, et al. Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. J Clin Oncol 2009; 27. Abstract e11566.
44. Delaloge S, Tedesco KL, Blum J, et al. Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2 + ++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2009; 27. Abstract 1010.
45. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-14.
46. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27. Abstract CRA501.
47. Fumoleau P, Llombart-Cussac A, Roche H, et al. Clinical activity of ixabepilone, a novel epothilone B analog, across the breast cancer disease continuum. Eur J Cancer 2007; 5 (Suppl). Abstract 2119.
48. Rugo HS, Roche H, Thomas ES, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Cancer Res 2009; 69 (Suppl 2). Abstract 3057.
49. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
50. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-6.
51. Carey LA, Mayer E, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26. Abstract 1009.
52. Nechushtan H, Steinberg H, Peretz T,. Preliminary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients. J Clin Oncol 2009; 27. Abstract e12018.
53. O'Shaughnessy J, Weckstein DJ, Vukelja S, et al. Randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106 (Suppl 1). Abstract 308.
54. Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. Cancer Res 2009; 69 (Suppl 2). Abstract 3118.
55. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-903. (Pubitemid 30624678)
56. Moynahan ME, Cui TY, Jasin M,. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001; 61: 4842-50. (Pubitemid 32691900)
57. Leone JP, Guardiola V, Venkatraman A, et al. Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): retrospective analysis of 125 patients. J Clin Oncol 2009; 27. Abstract 625.
58. Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009; 20: 1185-92.
59. Kern P, Kolberg HC, Stoblen F, et al. Primary systemic chemotherapy with carboplatin AUC 6 and docetaxel 75 mg/m2 (q3w) in triple-negative early breast cancer. J Clin Oncol 2010; 28 (Suppl). Abstract e11063.
60. Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009; 124: 1457-62.
61. Kim T, Lee H, Han S, et al. The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. J Clin Oncol 2010; 28. Abstract 1071.
62. Cassier PA, Dufresne A, Blay JY, Fayette J,. Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag 2008; 4: 109-16. (Pubitemid 351460936)
63. Gaymes TJ, Shall S, MacPherson LJ, et al. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 2009; 94: 638-46.
64. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21. (Pubitemid 40559006)
65. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105: 17079-84.
66. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. NEJM 2009; 361: 123-34.
67. Rivera E, Lee J, Davies A,. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008; 13: 1207-23.
68. Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27: 526-34.
69. Twelves C, Loesch D, Blum JL, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; 28 (Suppl). Abstract CRA1004.
70. Twelves C, Akerele C, Wanders J, et al. Eribulin mesylate (E7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 2010; 21 (Suppl 8): viii96. Abstract 275O.
71. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA,. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010; 10: 160-3.
72. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010; 28. Abstract 1005.
73. Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly vs every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bevacizumab (pac/bev) as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27. Abstract 1029.
74. Bergh J, Greil N, Voytko N, et al. Sunitinib in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010; 28. Abstract LBA1010.
75. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010; 28. Abstract LBA1011.
76. Corkery B, Crown J, Clynes M, O'Donovan N,. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-7.
77. Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep 2009; 21: 413-7.
78. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-26. (Pubitemid 47596452)
79. Tryfonopoulos D, O'Donovan N, Corkery B, Clynes M, Crown J,. Activity of dasatinib with chemotherapy in triple-negative breast cancer cells. J Clin Oncol 2009; 27. Abstract e14605.
80. Somlo G,. Dasatinib plus capecitabine (Cap) for progressive advanced breast cancer (ABC): phase I study CA180004. J Clin Oncol 2009; 27. Abstract 1012.
81. Fornier MN, Morris PG, Abbruzzi A, et al. A phase I-II study of dasatinib (D) in combination with weekly (W) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC). Ann Oncol 2011; Mar 15 [epub ahead of print].
82. Ogawa Y, Hai E, Matsumoto K, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008; 13: 431-5.
83. Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009; 106: 8368-73.
84. Ordentlich P, Tee L, Huynh Y, Mee S, Mamuszka H, Lee G,. Ex-vivo analysis of the isoform selective histone deacetylase inhibitor entinostat in triple-negative breast cancer tumors. J Clin Oncol 2009; 27. Abstract e14597.
85. Seitz S, Schally AV, Gluck S, et al. Effective treatment of triple-negative breast cancer with targeted cytotoxic somatostatin analogue AN-162 (AEZS-124). J Clin Oncol 2009; 27. Abstract 619.